Nancy Sullivan, CEO of Illinois Ventures, invests in seed and early-stage research-derived companies primarily in life. See sector focus and contact routes.
Nancy Sullivan, CEO of Illinois Ventures, invests in seed and early-stage research-derived companies primarily in life sciences, information technologies, and physical sciences, typically providing ~$150,000 in $500,000 rounds via convertible notes[2]. Her notable portfolio includes public company Revolution Medicines (RVMD), biotech firms Cystetic Medicines and Sfunga Therapeutics, and tech ventures like Keywise AI and Psyonic[4][7]. Sullivan’s distinctive thesis centers on commercializing innovations from the University of Illinois (and later other regional sources) through proof-of-concept grants, seed funding, and venture capital to build companies that struggle to secure funding elsewhere[1][2].
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in Chicago.
Investors like Nancy Sullivan · Full investor directory · Investor access · Company funding database